Neupogen (Filgrastim)
- Medicine Name: Neupogen
- API: Filgrastim
- Dosage Form & Strength: Injection: 300 mcg/mL, 480 mcg/1.6 mL in a single-dose vial, and 300 mcg/0.5 mL, 480 mcg/0.8 mL in a single-dose prefilled syringe
- Manufactured By: Amgen Inc.
Neupogen (filgrastim) is a leukocyte growth factor used to
- reduce the incidence of infection‚ as manifested by febrile neutropenia (FN)‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer medicines associated with a significant incidence of serious neutropenia with fever.
- reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML).
- reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT).
- mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
- reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia.
- increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).
Recommended Dosage:
- Patients with Cancer Receiving Myelosuppressive Chemotherapy or Induction and/or Consolidation Chemotherapy for AML: The recommended starting dose is 5 mcg/kg/day subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous intravenous infusion.
- Patients with Cancer Undergoing Bone Marrow Transplantation: The recommended dose is 10 mcg/kg per day given as an intravenous infusion no longer than 24 hours.
- Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy: The recommended dose is 10 mcg/kg/day subcutaneous injection. Administer for at least 4 days before the first leukapheresis procedure and continue until the last leukapheresis.
- Patients with Congenital Neutropenia: The recommended starting dose is 6 mcg/kg subcutaneous injection twice daily.
- Patients with Cyclic or Idiopathic Neutropenia: The recommended starting dose is 5 mcg/kg given subcutaneous injection daily.
- Patients Acutely Exposed to Myelosuppressive Doses of Radiation: The recommended dosage is 10 mcg/kg/day administered by subcutaneous injection.
- Patients should be monitored for serious allergic reactions. Symptoms may include rash, difficulty breathing, and swelling of the face or throat. If an allergic reaction occurs, the medication should be discontinued immediately.
- Filgrastim can cause the spleen to enlarge and, in rare cases, rupture. Patients should seek immediate medical attention if they experience pain in the left upper abdomen or shoulder.
- Acute respiratory distress syndrome (ARDS) has been reported. Patients should be monitored for symptoms such as fever, shortness of breath, and fluid in the lungs.
- Bone pain is a common side effect. While it is usually manageable with pain relievers, it can be severe in some patients. Regular monitoring and symptomatic treatment are advised.
- Excessive white blood cell counts can occur, potentially leading to complications. Regular blood tests are necessary to monitor white blood cell levels and adjust dosages accordingly.
- Capillary leak syndrome (CLS), characterized by hypotension, hypoalbuminemia, and edema, has been reported in patients treated with filgrastim. Patients should be monitored for these symptoms, especially if they have a history of cardiovascular issues.
- Filgrastim can lead to a decrease in platelet count, increasing the risk of bleeding. Patients should have regular blood tests to monitor platelet levels and report any unusual bruising or bleeding to their healthcare provider.
What documents are required to import NEUPOGEN to India?
NEUPOGEN (filgrastim) injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
The order will be confirmed only after the receipt of:
- A valid prescription from the Doctor
- Import permit if applicable
NEUPOGEN (filgrastim injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Neupogen in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
IPN (Indian Pharma Network) can facilitate the supply of NEUPOGEN (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Neupogen injection price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network can source the NEUPOGEN (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Neupogen®?
Filgrastim is a Generic Name for the trade name drug Neupogen®.
What is the Manufacturer’s Name of Neupogen®?
Neupogen® is manufactured by Amgen Inc.
What is the dosage and form of Neupogen® supplied?
Neupogen® is supplied as injections: 300 mcg/mL, 480 mcg/1.6 mL in a single-dose vial, and 300 mcg/0.5 mL, 480 mcg/0.8 mL in a single-dose prefilled syringe for subcutaneous or intravenous.
What are the most common side effects of Neupogen®?
The most common side effects of Neupogen® are bone pain, muscle aches, fatigue, headache, and nausea.
How much does Neupogen® cost in India?
Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Neupogen in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Neupogen®?
Neupogen® should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) and protected from light. Do not freeze or shake.
Is it safe to buy Neupogen® online in India?
Yes, one can buy Neupogen online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Neupogen® through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.